Adrenocorticotropic Hormone [ACTH] Market (Source: Natural and Synthetic; Indication: Rheumatology, Neurology, Nephrotic Syndrome, Ophthalmology, and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2030

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Adrenocorticotropic Hormone (ACTH) Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, 2017–2030

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Top 3 Players Operating in the Market Space

    5.2. Regulatory Scenario

    5.3. Export-Import Scenario

    5.4. Comparison Study of Synthetic & Natural Adrenocorticotropic Hormone

    5.5. Pipeline Analysis

    5.6. COVID-19 Pandemic Impact on Industry

6. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, by Source

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Source, 2017–2030

        6.3.1. Natural

        6.3.2. Synthetic

    6.4. Market Attractiveness Analysis, by Source

7. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, by Indication

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Indication, 2017–2030

        7.3.1. Rheumatology

        7.3.2. Neurology

        7.3.3. Nephrotic Syndrome

        7.3.4. Ophthalmology

        7.3.5. Others

    7.4. Market Attractiveness Analysis, by Indication

8. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2030

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Country/Region

10. North America Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Source, 2017–2030

        10.2.1. Natural

        10.2.2. Synthetic

    10.3. Market Value Forecast, by Indication, 2017–2030

        10.3.1. Rheumatology

        10.3.2. Neurology

        10.3.3. Nephrotic Syndrome

        10.3.4. Ophthalmology

        10.3.5. Others

    10.4. Market Value Forecast, by Distribution Channel, 2017–2030

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. Market Value Forecast, by Country, 2017–2030

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Source

        10.6.2. By Indication

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Source, 2017–2030

        11.2.1. Natural

        11.2.2. Synthetic

    11.3. Market Value Forecast, by Indication, 2017–2030

        11.3.1. Rheumatology

        11.3.2. Neurology

        11.3.3. Nephrotic Syndrome

        11.3.4. Ophthalmology

        11.3.5. Others

    11.4. Market Value Forecast, by Distribution Channel, 2017–2030

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Market Value Forecast, by Country/Sub-Region, 2017–2030

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Source

        11.6.2. By Indication

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-Region

12. Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Source, 2017–2030

        12.2.1. Natural

        12.2.2. Synthetic

    12.3. Market Value Forecast, by Indication, 2017–2030

        12.3.1. Rheumatology

        12.3.2. Neurology

        12.3.3. Nephrotic Syndrome

        12.3.4. Ophthalmology

        12.3.5. Others

    12.4. Market Value Forecast, by Distribution Channel, 2017–2030

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Market Value Forecast, by Country/Sub-Region, 2017–2030

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Source

        12.6.2. By Indication

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-Region

13. Latin America Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Source, 2017–2030

        13.2.1. Natural

        13.2.2. Synthetic

    13.3. Market Value Forecast, by Indication, 2017–2030

        13.3.1. Rheumatology

        13.3.2. Neurology

        13.3.3. Nephrotic Syndrome

        13.3.4. Ophthalmology

        13.3.5. Others

    13.4. Market Value Forecast, by Distribution Channel, 2017–2030

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Market Value Forecast, by Country/Sub-Region, 2017–2030

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Source

        13.6.2. By Indication

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-Region

14. Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Source, 2017–2030

        14.2.1. Natural

        14.2.2. Synthetic

    14.3. Market Value Forecast, by Indication, 2017–2030

        14.3.1. Rheumatology

        14.3.2. Neurology

        14.3.3. Nephrotic Syndrome

        14.3.4. Ophthalmology

        14.3.5. Others

    14.4. Market Value Forecast, by Distribution Channel, 2017–2030

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Market Value Forecast, by Country/Sub-Region, 2017–2030

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Source

        14.6.2. By Indication

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-Region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company, 2020

    15.3. Company Profiles

        15.3.1. Ambio Pharm, Inc.

            15.3.1.1. Company Description

            15.3.1.2. Business Overview

            15.3.1.3. Financial Overview

            15.3.1.4. Strategic Overview

            15.3.1.5. SWOT Analysis

        15.3.2. Armor Pharma

            15.3.2.1. Company Description

            15.3.2.2. Business Overview

            15.3.2.3. Financial Overview

            15.3.2.4. Strategic Overview

            15.3.2.5. SWOT Analysis

        15.3.3. Avantor, Inc.

            15.3.3.1. Company Description

            15.3.3.2. Business Overview

            15.3.3.3. Financial Overview

            15.3.3.4. Strategic Overview

            15.3.3.5. SWOT Analysis

        15.3.4. BCN Peptides S.A.

            15.3.4.1. Company Description

            15.3.4.2. Business Overview

            15.3.4.3. Financial Overview

            15.3.4.4. Strategic Overview

            15.3.4.5. SWOT Analysis

        15.3.5. BIOVECTRA

            15.3.5.1. Company Description

            15.3.5.2. Business Overview

            15.3.5.3. Financial Overview

            15.3.5.4. Strategic Overview

            15.3.5.5. SWOT Analysis

        15.3.6. Ferring B.V.

            15.3.6.1. Company Description

            15.3.6.2. Business Overview

            15.3.6.3. Financial Overview

            15.3.6.4. Strategic Overview

            15.3.6.5. SWOT Analysis

        15.3.7. Hikma Pharmaceuticals plc

            15.3.7.1. Company Description

            15.3.7.2. Business Overview

            15.3.7.3. Financial Overview

            15.3.7.4. Strategic Overview

            15.3.7.5. SWOT Analysis

        15.3.8. Mallinckrodt Pharmaceuticals

            15.3.8.1. Company Description

            15.3.8.2. Business Overview

            15.3.8.3. Financial Overview

            15.3.8.4. Strategic Overview

            15.3.8.5. SWOT Analysis

        15.3.9. Merck KGaA

            15.3.9.1. Company Description

            15.3.9.2. Business Overview

            15.3.9.3. Financial Overview

            15.3.9.4. Strategic Overview

            15.3.9.5. SWOT Analysis

        15.3.10. Novartis AG

            15.3.10.1. Company Description

            15.3.10.2. Business Overview

            15.3.10.3. Financial Overview

            15.3.10.4. Strategic Overview

            15.3.10.5. SWOT Analysis

        15.3.11. Novus Biologicals

            15.3.11.1. Company Description

            15.3.11.2. Business Overview

            15.3.11.3. Financial Overview

            15.3.11.4. Strategic Overview

            15.3.11.5. SWOT Analysis

        15.3.12. Pfizer, Inc.

            15.3.12.1. Company Description

            15.3.12.2. Business Overview

            15.3.12.3. Financial Overview

            15.3.12.4. Strategic Overview

            15.3.12.5. SWOT Analysis

        15.3.13. Piramal Pharma Solutions

            15.3.13.1. Company Description

            15.3.13.2. Business Overview

            15.3.13.3. Financial Overview

            15.3.13.4. Strategic Overview

            15.3.13.5. SWOT Analysis

        15.3.14. PolyPeptide Group

            15.3.14.1. Company Description

            15.3.14.2. Business Overview

            15.3.14.3. Financial Overview

            15.3.14.4. Strategic Overview

            15.3.14.5. SWOT Analysis

        15.3.15. SAJJALA BIO LABS

            15.3.15.1. Company Description

            15.3.15.2. Business Overview

            15.3.15.3. Financial Overview

            15.3.15.4. Strategic Overview

            15.3.15.5. SWOT Analysis

        15.3.16. Sichuan Xieli Pharmaceutical Co., Ltd.

            15.3.16.1. Company Description

            15.3.16.2. Business Overview

            15.3.16.3. Financial Overview

            15.3.16.4. Strategic Overview

            15.3.16.5. SWOT Analysis

        15.3.17. Viatris Inc.

            15.3.17.1. Company Description

            15.3.17.2. Business Overview

            15.3.17.3. Financial Overview

            15.3.17.4. Strategic Overview

            15.3.17.5. SWOT Analysis